Form 6-K Ascendis Pharma A/S For: Nov 14
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
Ascendis Pharma (ASND) PT Lowered to $200 at Citi
November 15, 2024 7:10 AM ESTCiti analyst David Lebowitz lowered the price target on Ascendis Pharma (NASDAQ: ASND) to $200.00 (from $207.00) while maintaining a Buy rating.
The analyst comments "Ascendis reported 3Q24 financial results, missing Street estimates on topline revenue and GAAP EPS, as the Skytrofa challenges that emerged... More
Ascendis Pharma (ASND) PT Lowered to $180 at Oppenheimer
November 15, 2024 6:21 AM ESTOppenheimer analyst Leland Gershell lowered the price target on Ascendis Pharma (NASDAQ: ASND) to $180.00 (from $190.00) while maintaining a Outperform rating.
The analyst comments "ASND reported 3Q net loss of 99.2M vs. our expected 110.2M as management continues to effectively manage expenses. Skytrofa revenue of... More
